Search - tctmd.com

Displaying 61 - 80 of 100

Sort: Relevancy | Date

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Daily News

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Shelley Wood

January 15, 2019

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Conference News ESC 2018

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

L.A. McKeown

August 31, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

Advertisement

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Top News in Policy & Practice: 2018

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

Alirocumab Price Slashed in Deal With Express Scripts

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content